← Leaderboards
Michael N Teng
University Of South Florida
$2,872,563
Attributed
$4,091,090
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $620.6K · FY2009–25$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,091,090 · 3
By mechanism
R01$2,984,125 · 2
P01$1,106,965 · 1
Top collaborators
- Jose S Jalife3 shared
- Sami Fouad Noujaim3 shared
Most similar at University Of South Florida
Same institution · by research overlap
- Jose S Jalife$14,345,410
- Sami Fouad Noujaim$6,105,146
Others in their field
Top investigators on “Affect”
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Judith S. Currier · University Of California Los Angeles$287,585,588
- Chanza Baytop · Westat, Inc.$271,217,917
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$209,385,844
- David Heimbrook · Leidos Biomedical Research, Inc.$168,138,264
- Daniel R Kuritzkes · Brigham And Women'S Hospital$151,687,019
Research focus
AffectCellsIn VitroMutantPlayRecombinantsRespiratory Syncytial VirusRespiratory Tract InfectionsChildhoodVirus ReplicationElderlyProteinsSignal TransductionAntiviral AgentsPathway InteractionsRespiratory Syncytial Virus VaccinesViralPreventMonoclonal AntibodiesMutationAmino AcidsMorbidity - Disease RateIn VivoAsthma
Grant awards (13)
Peptibodies As Novel Therapies in Atrial Fibrillation$609,261
R01 · FY2025 · HL
Peptibodies As Novel Therapies in Atrial Fibrillation$597,933
R01 · FY2024 · HL
Peptibodies As Novel Therapies in Atrial Fibrillation$620,596
R01 · FY2023 · HL
Project 1: Dr. Teng$270,952
P01 · FY2019 · AI · contact PI
Project 1: Dr. Teng$208,339
P01 · FY2018 · AI · contact PI
Project 1: Dr. Teng$250,928
P01 · FY2017 · AI · contact PI
Project 1: Dr. Teng$250,654
P01 · FY2016 · AI · contact PI
Project 1: Dr. Teng$126,092
P01 · FY2015 · AI · contact PI
Akt as a therapeutic target for respiratory syncytial virus$288,149
R01 · FY2012 · AI · contact PI
Akt as a therapeutic target for respiratory syncytial virus$288,149
R01 · FY2011 · AI · contact PI
Akt as a therapeutic target for respiratory syncytial virus$291,060
R01 · FY2010 · AI · contact PI
Akt as a therapeutic target for respiratory syncytial virus$204,978
R01 · FY2009 · AI · contact PI
Akt as a therapeutic target for respiratory syncytial virus$83,999
R01 · FY2009 · AI · contact PI